Hayek Kallen Investment Management Has $306,000 Holdings in CVS Health Co. (NYSE:CVS)

Hayek Kallen Investment Management cut its position in CVS Health Co. (NYSE:CVS - Free Report) by 64.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,822 shares of the pharmacy operator's stock after selling 12,484 shares during the quarter. Hayek Kallen Investment Management's holdings in CVS Health were worth $306,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Dodge & Cox increased its position in shares of CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares during the period. Capital World Investors grew its position in CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after buying an additional 12,819,148 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of CVS Health by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock valued at $1,211,582,000 after buying an additional 689,867 shares in the last quarter. Capital International Investors boosted its stake in shares of CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock worth $1,196,989,000 after acquiring an additional 1,212,126 shares in the last quarter. Finally, Pzena Investment Management LLC raised its position in shares of CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after purchasing an additional 6,475,271 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of NYSE:CVS traded up $0.07 during midday trading on Tuesday, hitting $65.00. The company's stock had a trading volume of 9,300,803 shares, compared to its average volume of 11,176,858. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $71.45. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The stock has a market capitalization of $81.95 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 0.98 and a beta of 0.57. The stock's 50 day simple moving average is $66.45 and its 200 day simple moving average is $58.75.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, research analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.09%. CVS Health's payout ratio is presently 72.68%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Evercore ISI boosted their price objective on CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Monday, January 27th. Wells Fargo & Company raised their price objective on shares of CVS Health from $68.00 to $73.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. UBS Group decreased their target price on CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a research report on Tuesday, February 11th. Argus set a $77.00 price objective on CVS Health in a research report on Tuesday, February 18th. Finally, Barclays upped their target price on CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $71.83.

Insider Buying and Selling

In other CVS Health news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.